Merck has just cut a deal with Idera for all their products except the vaccines. Imoxine is a vaccine adjuvant. Idera have only just completed enrollment for their phase2 in RCC with Imoxine. Imoxine was the compound used in combination with Coramsine in the impressive mouse test on Mesothelioma. As the combination was so successful it would be nice if Merck were interested in Coramsine, considering what they are paying for Imoxine. Imoxine is a TLR9 agonist. Just last month Pfizer bought out Coley to get hold of their product which is very similar. There are others out there.
"AP Idera Cleared for Merck Licensing Deal Wednesday February 6, 10:05 am ET Idera Pharmaceuticals Gets Regulatory Antitrust Clearance for Deal With Germany-Based Merck
CAMBRIDGE, Mass. (AP) -- Biotechnology company Idera Pharmaceuticals Inc. said Wednesday it passed a regulatory antitrust review and will move ahead on a licensing deal with Germany's Merck KGaA. Idera is licensing cancer treatment applications for two lead drug candidates to Merck. The regulatory clearance triggers an upfront fee of $40 million to Idera, which can also receive development milestone payments worth up to $381 million and royalties on future sales.
The deal excludes Idera's cancer vaccines, which are a separate class of therapies that work by building up the immune system's defenses in order to fight off cancer. Idera already has a deal with Whitehouse Station, N.J.-based Merck & Co. covering cancer vaccines.
Shares of Idera rose 15 cents to $10.50 in morning trading."
SBP Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
